Variable | CRE Colonization (n = 25) | Control (n = 75) | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|---|
OR (95% CI) | P-value | OR (95% CI) | P-value | |||
Patient characteristics | ||||||
 Man gender (Male) | 14 (56.00%) | 48 (64.00%) | 0.65 (0.21–2.00) | 0.45 |  |  |
 Age | 63.48 ± 22.81 | 60.76 ± 19.01 | 1.01 (0.98–1.05) | 0.36 |  |  |
 Transferring from another hospital | 10 (40.00%) | 37 (49.33%) | 0.92 (0.29–2.92) | 0.88 |  |  |
Underlying diseases | ||||||
 PITT Scores | 2.28 ± 1.86 | 2.98 ± 2.09 | 0.79 (0.54–1.15) | 0.22 |  |  |
 APACHE II Scores | 17.16 ± 7.18 | 15.74 ± 8.13 | 1.10 (1.01–1.20) | 0.05 | 0.40 (0.09–1.71) | 0.22 |
 Hypertension | 13 (52.00%) | 38 (50.66%) | 0.62 (0.18–2.15) | 0.42 |  |  |
 Diabetes | 12 (48.00%) | 20 (26.67%) | 3.97 (1.16–13.62) | 0.03 | 4.30 (0.67–27.306) | 0.12 |
 Tuberculosis | 2 (8.00%) | 4 (5.33%) | 0.94 (0.10–8.50) | 0.95 |  |  |
 Hepatitis B | 2 (8.00%) | 3 (4.00%) | 2.17 (0.24–19.57) | 0.09 |  |  |
 Tumour | 12 (48.00%) | 21 (28.00%) | 2.88 (0.85–9.72) | 0.09 |  |  |
 Respiratory diseases | 17 (68.00%) | 36 (48.00%) | 2.64 (0.76–9.14) | 0.13 |  |  |
 COPD | 9 (36.00%) | 5 (6.67%) | 0.92 (0.20–4.20) | 0.91 |  |  |
 Hepatobiliary disease | 8 (32.00%) | 26 (34.67%) | 0.63 (0.18–2.10) | 0.47 |  |  |
 Gastrointestinal disease | 6 (24.00%) | 27 (36.00%) | 0.36 (0.09–1.46) | 0.15 |  |  |
 Chronic kidney disease | 6 (24.00%) | 21 (28.00%) | 0.75 (0.21–2.70) | 0.66 |  |  |
 Urinary system disease | 10 (40.00%) | 6 (8.00%) | 7.71 (2.21–26.83) | 0.001 | 18.06 (3.31–98.62) | 0.001 |
 Cardiovascular disease | 15 (60.00%) | 41 (54.67%) | 0.87 (0.27–2.80) | 0.82 |  |  |
 Coronary heart disease | 7 (28.00%) | 10 (13.33%) | 4.26 (1.12–16.28) | 0.03 | 3.29 (0.91–11.98) | 0.07 |
 Neurological disease | 9 (36.00%) | 18 (24.00%) | 2.27 (0.64–7.99) | 0.20 |  |  |
 Disease of immune system | 1 (4.00%) | 5 (6.67%) | 0.22 (0.02–2.85) | 0.25 |  |  |
 Hematological system diseases | 4 (16.00%) | 16 (21.33%) | 1.47 (0.32–6.72) | 0.62 |  |  |
 Endocrine System Diseases | 15 (60.00%) | 28 (37.33%) | 3.16 (1.05–9.54) | 0.04 | 1.62 (0.33–7.99) | 0.55 |
 Surgery in the past 6 months | 2 (8.00%) | 16 (21.33%) | 0.32 (0.05–1.99) | 0.22 |  |  |
 Multiple organ dysfunction syndrome | 6 (24.00%) | 8 (10.67%) | 6.27 (1.35–29.05) | 0.02 |  |  |
 Transplant | 4 (16.00%) | 11 (14.67%) | 1.82 (0.43–7.64) | 0.42 |  |  |
 Urinary tract infection | 10 (40.00%) | 12 (16.00%) | 3.64 (0.78–16.87) | 0.09 |  |  |
 Respiratory infection | 21 (84.00%) | 51 (68.00%) | 2.20 (0.37–12.92) | 0.38 |  |  |
 Abdominal infection | 8 (32.00%) | 2 (2.67%) | 0.48 (0.05–4.68) | 0.53 |  |  |
 Septic shock | 1 (4.00%) | 9 (12.00%) | 0.99 (0.95–1.02) | 0.53 |  |  |
 Severe anemia | 5 (20.00%) | 17 (26.15%) | 1.06 (0.27–4.13) | 0.94 |  |  |
 Glucocorticoid | 7 (28.00%) | 12 (16.00%) | 2.58 (0.86–9.72) | 0.21 |  |  |
 Cardiotonic | 2 (8.00%) | 5 (6.67%) | 0.78 (0.08–7.87) | 0.84 |  |  |
 Receipt of total parenteral Nutrition (days) | 39.00 ± 57.47 | 16.71 ± 25.33 | 0.99 (0.95–1.02) | 0.53 |  |  |
 Urinary catheter (days) | 56.08 ± 60.35 | 21.80 ± 26.07 | 1.04 (0.99–1.09) | 0.08 |  |  |
 Nasal catheter (days) | 35.38 ± 48.75 | 21.59 ± 36.98 | 0.97 (0.92–1.04) | 0.16 |  |  |
 Mechanical ventilation (days) | 34.64 ± 48.61 | 15.15 ± 19.01 | 1.02 (0.98–1.09) | 0.16 |  |  |
 Trachea cannula | 24.80 ± 48.02 | 12.65 ± 24.27 | 0.98 (0.95–1.03) | 0.55 |  |  |
 Tracheotomy | 10 (40.00%) | 31 (41.33%) | 0.17 (0.02–1.28) | 0.08 |  |  |
 Bronchoscopy | 12 (48.00%) | 13 (17.33%) | 8.15 (1.61–41.22) | 0.01 | 4.05 (1.30–12.60) | 0.01 |
 Drainage tube | 19 (76.00%) | 55 (73.33%) | 0.31 (0.05–1.76) | 0.18 |  |  |
 Penicillin | 5 (20.00%) | 17 (22.67%) | 0.60 (0.14–2.55) | 0.48 |  |  |
 Cephalosporins | 8 (32.00%) | 25 (33.33%) | 0.37 (0.08–1.61) | 0.19 |  |  |
 Carbapenem | 10 (40.00%) | 24 (32.00%) | 1.12 (0.32–3.84) | 0.86 |  |  |
 Fluoroquinolone | 5 (20.00%) | 11 (14.67%) | 0.87 (018–4.30) | 0.87 |  |  |
 Tetracycline | 3 (12.00%) | 4 (5.33%) | 0.93 (0.14–5.90) | 0.92 |  |  |
 Glycopeptide | 3 (12.00%) | 12 (16.00%) | 0.20 (0.03–1.15) | 0.07 |  |  |
 Tigecycline | 4 (16.00%) | 3 (4.00%) | 1.94 (0.27–13.98) | 0.51 |  |  |
 Combined use of antibiotics | 18 (72.00%) | 32 (42.67%) | 5.91 (1.20–29.16) | 0.03 | 3.60 (1.18–10.93) | 0.02 |